Manserin as possible marker of prostate cancer progression

“Manserin” is a novel peptide originally derived from a larger secretory protein called secretogranin II. A newly published paper suggests that expression of manserin in human prostate cancer tissues may correlate with risk for clinically significant and progressive forms of prostate cancer.

Nishikawa et al. sought to assess the expression of manserin in human prostate tissues cancers and to correlate the level of manserin expression with pathologic outcomes and progression-free survival in recently diagnosed men with prostate cancer.

They classified a set of 89 recently diagnosed patients into four groups based on their Gleason scores (Gleason score 6, 7, 8, and 9 or 10). They then attempted to correlate manserin expression (based on immunohistochemical tests) with Gleason score. In addition, to see if manserin expression had prognostic significance, they examined data from 48 of their 89 patients who were diagnosed with T3/4 prostate cancer and who all received androgen deprivation therapy (ADT) as first-line treatment.

The results of their study showed that:

  • The rate of expression of manserin in men as classified by Gleason score were
    • 0.0 percent in men with Gleason 6 disease
    • 20.0 percent in men with Gleason 7 disease
    • 35.0 percent in men with Gleason 8 disease
    • 48.1 percent in men with Gleason 9 or 10 disease
  • Manserin-positive rates were positively correlated with Gleason scores (P = 0.0001).
  • Median times to cancer progression in men diagnosed with T3/4 prostate cancer were
    • 8 months in men expressing manserin (n = 8)
    • 28 months in men not expressing manserin (n = 40) 
  • On the basis of univariate analysis, manserin expression, clinical stage T4, and high Gleason sum were significantly associated with risk for progressive prostate cancer.
  • On the basis of multivariate analysis, only manserin expression (hazard ratio [HR] = 4.99, P = 0.01) and clinical stage T4 (HR = 4.77, P = 0.03) were independent risk factors for disease progression.

It is possible that manserin may have future utility as a marker for prostate cancer progression. Clearly there is a great deal of work to be done before this can be established, but manserin levels can clearly be assayed with great accuracy in biopsy and surgical samples of prostate cancer tissue, and without the subjectivity associated with assignment of Gleason scores.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: